- Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies
- The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030
- The monoclonal antibodies market was valued at $210.06 billion in 2022, and it is expected to reach $494.53 billion by 2030
- The nanobody market was valued $237.1 million in 2021 and is expected reach a value of $1.07 billion by 2028
- BiondVax is uniquely positioned to rapidly advance from R&D towards commercialization
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is planning a rapid development path that leverages the company’s expertise and capabilities in biological drug development and manufacturing. Using a platform of alpaca-derived nanobodies (NanoAbs), BiondVax is targeting large market disorders underserved by current therapeutics, including COVID-19, asthma, and psoriasis. BiondVax’s diverse and growing pipeline is being developed in collaboration with the world renowned Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) in Germany.
The biologics market, which is comprised of any pharmaceutical drug product manufactured in, extracted from, or semi-synthesized from biological sources, was valued at $366.5 billion in 2021 and is expected to grow at a CAGR of 7.15%, resulting in a value of $719.94 billion by 2030. The introduction of targeted…
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.